PMID- 37653016
OWN - NLM
STAT- MEDLINE
DCOM- 20230904
LR  - 20230906
IS  - 1999-6187 (Electronic)
IS  - 1009-3419 (Print)
IS  - 1009-3419 (Linking)
VI  - 26
IP  - 7
DP  - 2023 Jul 20
TI  - [Exploration of the Perturbation of PKIG in Lung Squamous Cell Carcinoma and the 
      Role in Tumor Microenvironment Based on Bioinformatics Method].
PG  - 523-537
LID - 10.3779/j.issn.1009-3419.2023.102.24 [doi]
AB  - BACKGROUND: Lung cancer is the leading cause of cancer-related death worldwide, 
      and patients have limited survival benefits from traditional treatments such as 
      surgery, radiotherapy and chemotherapy. As a new treatment for lung cancer, 
      immunotherapy has significantly prolonged the overall survival (OS) of patients. 
      However, only some patients can benefit from it. We need to explore immunotherapy 
      biomarkers more deeply to screen for advantages. METHODS: The original data were 
      downloaded from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) 
      database, and the immunological and prognostic genes of lung squamous cell 
      carcinoma (LUSC) were screened using R software and TIMER database. The 
      expression of target genes was studied in TCGA and GEO databases, and Gene 
      Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment 
      analysis and correlation analysis with tumor immune characteristics were 
      performed by R software and TISIDB database. RESULTS: We screened out a gene 
      related to immunity and prognosis, cAMP dependent protein kinase inhibitor gamma 
      (PKIG), which is significantly differentially expressed in LUSC and normal 
      tissues, and has important reference value for the diagnosis and prognosis 
      assessment of LUSC. PKIG differential genes are mainly concentrated in the 
      regulation of humoral immune response and other processes. The expression of PKIG 
      was positively correlated with the infiltration level of regulatory T cells 
      (Tregs) (r=0.340, P<0.001). In addition, the expression level of PKIG was 
      positively correlated with the expression of chemokines/chemokine receptors such 
      as chemokine C-C motif ligand 2 (CCL2) (r=0.503, P<0.001), CXC chemokine ligand 
      12 (CXCL12) (r=0.386, P<0.001) and CXC-chemokine receptor 4 (CXCR4) (r=0.492, 
      P<0.001), and immunoinhibitors such as programmed cell death protein 1 (PDCD1) 
      (r=0.359, P<0.001), cytotoxic T-lymphocyte associated antigen 4 (CTLA4) (r=0.375, 
      P<0.001) and T cell immunoglobulin and ITIM domains (TIGIT) (r=0.305, P<0.001) in 
      LUSC. CONCLUSIONS: The immunological and prognostic gene PKIG in lung squamous 
      cell carcinoma was screened through bioinformatics analysis. PKIG is highly 
      correlated with LUSC prognosis and immune microenvironment, and is expected to be 
      a potential biomolecular marker for LUSC immunotherapy.
FAU - Liu, Qing
AU  - Liu Q
AD  - Department of Thoracic Surgery, Lanzhou University Second Hospital, Lanzhou 
      University Second Clinical Medical College, 
Lanzhou 730030, China.
FAU - Li, Haitian
AU  - Li H
AD  - Department of Thoracic Surgery, Lanzhou University Second Hospital, Lanzhou 
      University Second Clinical Medical College, 
Lanzhou 730030, China.
FAU - Li, Bin
AU  - Li B
AD  - Department of Thoracic Surgery, Lanzhou University Second Hospital, Lanzhou 
      University Second Clinical Medical College, 
Lanzhou 730030, China.
FAU - Ren, Meiyu
AU  - Ren M
AD  - Department of Thoracic Surgery, Lanzhou University Second Hospital, Lanzhou 
      University Second Clinical Medical College, 
Lanzhou 730030, China.
FAU - Li, Zhenqing
AU  - Li Z
AD  - Department of Thoracic Surgery, Lanzhou University Second Hospital, Lanzhou 
      University Second Clinical Medical College, 
Lanzhou 730030, China.
FAU - Chen, Yuzhen
AU  - Chen Y
AD  - Department of Thoracic Surgery, Lanzhou University Second Hospital, Lanzhou 
      University Second Clinical Medical College, 
Lanzhou 730030, China.
FAU - Zheng, Zhizhong
AU  - Zheng Z
AD  - Department of Thoracic Surgery, Lanzhou University Second Hospital, Lanzhou 
      University Second Clinical Medical College, 
Lanzhou 730030, China.
FAU - Meng, Yuqi
AU  - Meng Y
AD  - Department of Thoracic Surgery, Lanzhou University Second Hospital, Lanzhou 
      University Second Clinical Medical College, 
Lanzhou 730030, China.
FAU - Feng, Haiming
AU  - Feng H
AD  - Department of Thoracic Surgery, Lanzhou University Second Hospital, Lanzhou 
      University Second Clinical Medical College, 
Lanzhou 730030, China.
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhongguo Fei Ai Za Zhi
JT  - Zhongguo fei ai za zhi = Chinese journal of lung cancer
JID - 101126433
RN  - 0 (Ligands)
SB  - IM
MH  - Humans
MH  - *Lung Neoplasms/genetics
MH  - Tumor Microenvironment/genetics
MH  - Ligands
MH  - *Carcinoma, Non-Small-Cell Lung
MH  - *Carcinoma, Squamous Cell/genetics
MH  - Lung
PMC - PMC10476207
OTO - NOTNLM
OT  - Bioinformatics
OT  - Immunotherapy
OT  - Lung neoplasms
OT  - Tumor microenvironment
OT  - cAMP-dependent protein kinase inhibitor gamma
EDAT- 2023/09/01 00:41
MHDA- 2023/09/04 06:42
PMCR- 2023/07/20
CRDT- 2023/08/31 23:24
PHST- 2023/09/04 06:42 [medline]
PHST- 2023/09/01 00:41 [pubmed]
PHST- 2023/08/31 23:24 [entrez]
PHST- 2023/07/20 00:00 [pmc-release]
AID - 10.3779/j.issn.1009-3419.2023.102.24 [doi]
PST - ppublish
SO  - Zhongguo Fei Ai Za Zhi. 2023 Jul 20;26(7):523-537. doi: 
      10.3779/j.issn.1009-3419.2023.102.24.